News
all
press releases
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
Zacks
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
Zacks
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens
The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.
Stocktwits

Advertisement|Remove ads.